Status:
COMPLETED
Safety of TG100-115 for Heart Attack Treated With Angioplasty
Lead Sponsor:
TargeGen
Conditions:
Myocardial Infarction
Eligibility:
All Genders
18-80 years
Phase:
PHASE1
PHASE2
Brief Summary
TG100-115 is able to reduce the size of heart attacks in pre-clinical models. The hypothesis of this study is that TG100-115 can be given safely to patients who suffer a heart attack and undergo angio...
Eligibility Criteria
Inclusion
- Age 18-80 yrs
- ECG patterns consistent with an acute anterior myocardial infarction with ST segment elevation of 2mm in two contiguous ECG leads among leads V1-V4.
- Have prolonged, continuous (lasting at least 20 mins) signs and symptoms of myocardial ischemia not eliminated with nitrates.
- Intent to proceed to primary PCI within 6 hours of chest pain onset
- Sign an informed consent form and be willing to attend follow-up visits for safety and other study assessments.
Exclusion
- Female of childbearing potential.
- History of previous myocardial infarction.
- History of congestive heart failure.
- Requirement for a cardiac pacemaker or defibrillator.
- Cardiogenic shock.
- Patients previously treated with thrombolytic therapy.
- Myocardial ischemia precipitated by a condition other than atherosclerotic coronary artery disease.
Key Trial Info
Start Date :
January 1 2005
Trial Type :
INTERVENTIONAL
End Date :
January 1 2008
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT00103350
Start Date
January 1 2005
End Date
January 1 2008
Last Update
May 20 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
David Holmes, MD
Rochester, Minnesota, United States, 55905